Exelixis (EXEL)
(Real Time Quote from BATS)
$23.78 USD
+0.08 (0.34%)
Updated Apr 29, 2024 01:30 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXEL 23.78 +0.08(0.34%)
Will EXEL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXEL
What's in the Cards for Amgen (AMGN) This Earnings Season?
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
EXEL vs. REGN: Which Stock Is the Better Value Option?
Other News for EXEL
The Top 3 Biotech Stocks to Buy in April 2024
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis slips as Barclays downgrades on lack of catalysts
Exelixis just downgraded at Barclays, here's why
Barclays downgrades Exelixis (EXEL) to a Hold